Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Ptc Therapeutics (PTCT) over the last 9 years, with Q3 2025 value amounting to $15.8 million.

  • Ptc Therapeutics' Cost of Revenue rose 4547.38% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year decrease of 1977.28%. This contributed to the annual value of $57.4 million for FY2024, which is 1235.07% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Cost of Revenue stood at $15.8 million, which was up 4547.38% from $11.4 million recorded in Q2 2025.
  • Ptc Therapeutics' Cost of Revenue's 5-year high stood at $29.1 million during Q4 2023, with a 5-year trough of $6.5 million in Q3 2021.
  • Over the past 5 years, Ptc Therapeutics' median Cost of Revenue value was $11.4 million (recorded in 2025), while the average stood at $12.6 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Cost of Revenue surged by 16730.93% in 2023, and later plummeted by 4407.93% in 2024.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Cost of Revenue stood at $9.3 million in 2021, then increased by 16.79% to $10.9 million in 2022, then surged by 167.31% to $29.1 million in 2023, then crashed by 44.08% to $16.3 million in 2024, then fell by 3.08% to $15.8 million in 2025.
  • Its Cost of Revenue was $15.8 million in Q3 2025, compared to $11.4 million in Q2 2025 and $12.9 million in Q1 2025.